MAXCYTE, INC. Logo

MAXCYTE, INC.

Provides a scalable, non-viral electroporation platform for cell therapy development.

MXCT | US

Overview

Corporate Details

ISIN(s):
US57777K1060 (+2 more)
LEI:
54930053YHXULRFCU991
Country:
United States of America
Address:
9713 KEY WEST AVENUE,, 20850 ROCKVILLE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

MaxCyte, Inc. is a commercial-stage cell-engineering company providing enabling platform technologies for the discovery, development, and commercialization of cell-based therapeutics. The company's core offering is its proprietary, non-viral Flow Electroporation® technology, delivered through the scalable ExPERT™ platform. This system facilitates high-efficiency engineering of complex cell types for a wide range of applications, including cell therapy, protein production, cell-based assays, and gene editing. In addition to its technology platform, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate gene editing safety. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-26 11:14
Director's Dealing
Correction: Vesting of RSUs and PDMR Dealing
English 57.0 KB
2025-03-26 08:00
Director's Dealing
Vesting of RSUs and PDMR Dealing
English 55.7 KB
2025-03-25 11:30
Major Shareholding Notification
Holding(s) in Company
English 88.0 KB
2025-03-25 11:28
Major Shareholding Notification
Holding(s) in Company
English 87.7 KB
2025-03-25 11:26
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB
2025-03-25 11:22
Major Shareholding Notification
Holding(s) in Company
English 87.8 KB

Automate Your Workflow. Get a real-time feed of all MAXCYTE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MAXCYTE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MAXCYTE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gubra A/S Logo
CRO & biotech accelerating peptide drug discovery for metabolic and fibrotic diseases.
Denmark
GUBRA
HALOZYME THERAPEUTICS, INC. Logo
Licenses a drug delivery platform to biopharma, converting IV drugs to subcutaneous injections.
United States of America
HALO
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan
4593
HeartSciences Inc. Logo
AI-powered ECG technology for early detection of heart disease and advanced diagnostics.
United States of America
HSCS
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan
219A
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland
HRTIS
Hipower Energy Spolka Akcyjna Logo
Develops hydrogen solutions, mobile refueling, and CO2-to-methanol tech for energy markets.
Poland
HPE
HLB bioStep Co.,Ltd. Logo
South Korea
278650
HLB PANAGENE Co., LTD. Logo
A global leader in PNA technology for cancer diagnostics and precision medicine.
South Korea
046210
HLB SCIENCE Inc. Logo
Develops innovative therapeutics and diagnostics for infectious and neurodegenerative diseases.
South Korea
343090

Talk to a Data Expert

Have a question? We'll get back to you promptly.